- Emergex Vaccines Holding Limited acquired the fortune of Zosano Pharma Corporation. The sale was part of standard Zosano procedure Filed for bankruptcy in June.
- The Fortune acquired This includes intellectual property, license agreements and manufacturing facilities.
- It also includes Zosano’s proprietary microneedle array patch (MAP) system for intradermal drug delivery, including a reusable applicator, solid-coated microneedle array patch technology, product packaging, methods of formulation and microneedle coating, and specialty equipment.
- Emergex has previously conducted proof-of-concept studies in which Zosano’s MAP technology-based microneedle patches were coated with Emergex vaccine candidates and observed favorable shelf life characteristics.
- In May, Zosano its M207 program suspended to preserve its capital and liquidity resources.
- In addition, the Company’s remaining feasibility study with a pharmaceutical partner is expected to be completed this quarter.
- Novo Nordisk A/S NVO Paid $1 million once in advance to use Zosano’s patch system to develop transdermal versions of selected Novo glucagon-like peptide 1 (GLP-1) analogues. In 2015, the companies canceled the pact.
- Eli Lilly and Co LLY once partnered with Zosano and invested $15 million to commercialize a treatment for osteoporosis, but the companies later dissolved the pact.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
